drugset / Trial / NCT04837131
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs, and its effects on overall health and quality of life.
Timeline
- Start
- 2021-04-28
- Primary completion
- 2024-02-23
- Completion
- 2024-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |